How Oral Semaglutide Gets Absorbed: Molecular Dynamics Modeling Reveals the Mechanism
Pharmacokinetic modeling and molecular dynamics simulations revealed how oral semaglutide is absorbed in the stomach via SNAC enhancer, explaining the fasting requirement and variable bioavailability.
Quick Facts
What This Study Found
Molecular dynamics revealed SNAC creates local pH changes that protect semaglutide from degradation and promote gastric transcellular absorption, explaining fasting requirements and variable bioavailability.
Key Numbers
Semaglutide is absorbed mainly from the stomach. It's a lipid-modified alpha-helical peptide. Structural parameters were incorporated into pharmacokinetic models.
How They Did This
Pharmacokinetic population modeling of oral semaglutide absorption. Molecular dynamics simulations of semaglutide-SNAC-gastric membrane interactions. Bioavailability analysis.
Why This Research Matters
Understanding how oral semaglutide works at the molecular level enables design of better oral peptide formulations with higher bioavailability — potentially making oral GLP-1 drugs as effective as injections.
The Bigger Picture
Oral delivery of peptides was considered impossible until oral semaglutide proved it could work. Understanding the exact mechanism at the molecular level is essential for improving bioavailability and developing oral versions of other peptide drugs.
What This Study Doesn't Tell Us
Simulations are theoretical predictions. In vivo absorption involves additional complexity. Individual patient variability in gastric pH and motility affects real-world absorption.
Questions This Raises
- ?Can the SNAC mechanism be optimized to increase oral semaglutide bioavailability beyond 1%?
- ?Could molecular dynamics guide design of better enhancers for other oral peptide drugs?
- ?Would higher bioavailability oral formulations eliminate the need for fasting?
Trust & Context
- Key Stat:
- ~1% bioavailability explained Molecular simulations reveal SNAC creates local pH changes protecting semaglutide in the stomach, explaining why only ~1% reaches the bloodstream
- Evidence Grade:
- Moderate evidence: combined PK modeling and molecular dynamics providing mechanistic understanding supported by clinical pharmacokinetic data.
- Study Age:
- Published in 2025. Advances understanding of the first commercially successful oral peptide drug.
- Original Title:
- Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations.
- Published In:
- In silico pharmacology, 13(2), 103 (2025)
- Authors:
- Agarwal, Palak Nitin, Haworth, Ian S
- Database ID:
- RPEP-09780
Evidence Hierarchy
Frequently Asked Questions
Why must I take oral semaglutide on an empty stomach?
The SNAC enhancer creates a special local environment in the stomach that protects semaglutide from digestion and helps it cross the stomach lining. Food disrupts this process, dramatically reducing absorption. Taking it with only a sip of water maximizes the SNAC effect.
Why is oral semaglutide bioavailability so low?
Only about 1% of the oral dose reaches the bloodstream because the stomach is designed to break down proteins. SNAC helps but cannot fully overcome this barrier. Despite low bioavailability, the high dose in the tablet (3-14 mg vs 0.25-1 mg injected) compensates to achieve therapeutic levels.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09780APA
Agarwal, Palak Nitin; Haworth, Ian S. (2025). Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations.. In silico pharmacology, 13(2), 103. https://doi.org/10.1007/s40203-025-00393-7
MLA
Agarwal, Palak Nitin, et al. "Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations.." In silico pharmacology, 2025. https://doi.org/10.1007/s40203-025-00393-7
RethinkPeptides
RethinkPeptides Research Database. "Oral absorption of semaglutide: pharmacokinetic modeling and..." RPEP-09780. Retrieved from https://rethinkpeptides.com/research/agarwal-2025-oral-absorption-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.